title: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
abstract: To evaluate the literature about the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of cardiac disorders, specifically myocardial infarction (MI) and heart failure (HF).
  
  
  
  Searches were conducted in MEDLINE (1946-May 2016) and Excerpta Medica (1980-May 2016) using EMBASE with the search terms glucagon-like peptide 1, exenatide, albiglutide, liraglutide, dulaglutide, myocardial infarction, heart failure, and cardiovascular The references of relevant articles were reviewed to identify additional citations.
  
  
  
  Clinical trials were limited to the English language and human trials. In all, 18 trials explored the use of GLP-1 RAs in the treatment of cardiac disorders in patients with and without diabetes mellitus.
  
  
  
  Of the 18 trials reviewed, 11 trials studied the impact of GLP-1 RAs in MI. All showed a significant beneficial effect on various cardiac parameters. Favorable outcome improvements included myocardial blood flow, left ventricular (LV) function, and MI size. Seven trials reviewed the use of GLP-1 RAs in the treatment of HF. Three trials showed significant improvements in LV ejection fraction, cardiac index, and peak oxygen consumption.
  
  
  
  Limited data suggest that GLP-1 RAs may be effective for the treatment of cardiac disorders in patients with and without diabetes mellitus. These studies suggest that GLP-1 RAs may have potential pleiotropic beneficial effects in patients with cardiovascular disease beyond their role in managing diabetes. These medications may be cardioprotective after a MI but are less promising in HF.
authors.affiliation: Southwestern Oklahoma State University, Weatherford, OK, USA.
authors.forename: Jamie
authors.initials: J
authors.lastname: Wroge
authors.affiliation: Southwestern Oklahoma State University, Weatherford, OK, USA nancy.williams@swosu.edu.
authors.forename: Nancy Toedter
authors.initials: NT
authors.lastname: Williams
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000378:metabolism* / Q000627:therapeutic use; D004763:Glucagon-Like Peptides / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007141:Immunoglobulin Fc Fragments / Q000378:metabolism / Q000627:therapeutic use; D000069450:Liraglutide / Q000378:metabolism / Q000627:therapeutic use; D010455:Peptides / Q000378:metabolism / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000378:metabolism / Q000627:therapeutic use; D014688:Venoms / Q000378:metabolism / Q000627:therapeutic use; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D007004:Hypoglycemic Agents; D007141:Immunoglobulin Fc Fragments; D010455:Peptides; D011993:Recombinant Fusion Proteins; D014688:Venoms; C534611:rGLP-1 protein; D004763:Glucagon-Like Peptides; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide; C555680:dulaglutide; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: GLP-1 receptor agonists; heart failure; myocardial infarction